ADMA Biologics to report Q3 2026 financial results on Nov 4 with a live conference call.

ADMA Biologics announced it will release its third quarter 2026 financial results on November 4, 2026, after U.S. markets close. The company will hold a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates. ADMA is a U.S.-based biopharmaceutical firm specializing in plasma-derived biologics for immune-compromised patients. Investors and interested parties can register for the call or listen to the webcast, with a replay available on the company's website.

As of Oct 28, 2026 18:11 WIB, ADMA Biologics trades at USD 11.17 on Pluang, holding steady with a 0.00% change over the day. This price sits closer to its 52-week low of USD 7.60 than its 52-week high of USD 20.38, indicating the stock is currently in the lower half of its yearly range. The market capitalization stands at $2.51 billion, reflecting its mid-sized position in the health sector. Typical investors hold ADMA shares for about 19 days on Pluang.